Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.69 |
| ▸ | CNR2 | P34972 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 9/20 | 0.55 |
| ▸ | ITK | Q08881 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | BLK | P51451 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12518622 | 0.94 | BTK (0.77) | BTKCNR2MEN1ALDH1A1POLB | |
| SCHEMBL12519590 | 0.89 | CNR2 (0.60) | BTKCNR2MEN1ALDH1A1POLB | |
| SCHEMBL14771995 | 0.88 | CNR2 (0.61) | BTKCNR2MEN1ALDH1A1POLB | |
| SCHEMBL21110447 | 0.87 | BTK (0.91) | BTKCNR2ITKEGFR | |
| SCHEMBL21110443 | 0.86 | BTK (0.69) | BTKCNR2MEN1ALDH1A1POLB | |
| SCHEMBL14769194 | 0.84 | BTK (0.62) | BTKCNR2EGFRBLK | |
| SCHEMBL13498134 | 0.84 | ITK (0.62) | BTKMEN1MAPTKMT2ASYK | |
| SCHEMBL14791272 | 0.84 | CNR2 (0.58) | BTKCNR2MEN1ALDH1A1POLB | |
| SCHEMBL14769211 | 0.83 | CNR2 (0.60) | BTKCNR2MEN1ALDH1A1POLB | |
| SCHEMBL12519472 | 0.82 | BTK (1.00) | BTKITKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | BTK 261/4885CNR2 2355/4885MEN1 3174/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885CNR2 238/4885MEN1 606/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | BTK 261/4885CNR2 2355/4885MEN1 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.